HighLife, a medtech company developing a transcatheter implant for mitral valve regurgitation, has closed a $90 million funding round, according to Ventureburn. The raise will fund two parallel bets: a pivotal clinical study required to unlock the US market under FDA oversight, and an accelerated commercial push across Europe where the device is already in use.
The mitral valve sits between the left atrium and left ventricle and regulates blood flow through the heart's most critical pumping circuit. When it fails to close properly — a condition called mitral regurgitation — blood leaks backward, forcing the heart to work harder and eventually leading to heart failure. It is one of the most common structural heart conditions globally, yet surgical repair remains risky for older or frail patients, creating strong demand for catheter-based alternatives that avoid open-chest procedures.
HighLife's device is designed to be delivered via catheter, targeting patients who are poor candidates for conventional open-heart surgery. The company has been building clinical evidence in Europe, and the new capital marks its readiness to make the far more expensive and procedurally demanding move into the US regulatory pathway — a step that typically requires a randomized controlled trial enrolling hundreds of patients across multiple sites and can cost tens of millions of dollars on its own.
The $90 million round is substantial by medtech standards, particularly for a structural heart device that has not yet cleared US regulatory review. For context, the global transcatheter mitral valve market is projected by multiple industry analysts to reach several billion dollars over the next decade, driven largely by ageing populations in the US and Europe. Companies like Abbott, Edwards Lifesciences, and Tendyne — a subsidiary of Abbott — have spent years and hundreds of millions of dollars in the same space, underscoring both the opportunity and the capital intensity of competing here.
Europe represents HighLife's near-term revenue engine. The company already has commercial activity on the continent, and a portion of the fresh capital is earmarked to expand that presence — building out its hospital network, training interventional cardiologists, and generating the real-world outcomes data that will be critical for reimbursement negotiations with national health systems. Reimbursement remains the defining commercial hurdle in European medtech: device approval and clinical adoption are often separated by years of health-technology assessment.
The US study, meanwhile, is a longer-duration investment. FDA pivotal trials for structural heart devices routinely take three to five years from enrollment start to data readout, followed by a review process that can add another one to two years. That means HighLife's US commercial launch, if the study succeeds, is likely a half-decade away — but the strategic value of running the trial now is that it locks in the company's position before the market consolidates further around Abbott and Edwards.
Ventureburn's reporting does not name the lead investor or identify the other backers participating in the round, which limits visibility into the syndicate's composition and whether this is a new institutional entry or a continuation of existing shareholders doubling down. That detail matters: structural heart funding at this scale typically involves specialist life-sciences funds such as Sofinnova, Andera Partners, or Gimv, or strategic participation from a large medtech player positioning for an eventual acquisition.
For African investors and operators watching the continent's healthtech corridor, HighLife's raise is a reminder of the capital gap that separates device-stage medtech from software-led health startups. Most African healthtech funding flows toward diagnostics, telemedicine, pharmacy logistics, and health information systems — sectors where the path to revenue is shorter and regulatory complexity is lower. Device companies with African roots or African market ambitions face a structurally harder fundraising environment, both because of the clinical trial cost burden and because exit options via acquisition by global medtech strategics are less visible to local investors.
Why it matters: A $90 million medtech round for a catheter-based mitral valve device signals that specialist capital is still moving into structural heart despite a tighter global funding environment — and that the window for well-differentiated device companies to run US pivotal trials, before market consolidation closes off independent exits, remains open but is narrowing.